The location for Spring 2026 seminars is C1-017.
Spring 2026 Seminar Schedule
| Date | Time | Presenter | seminar title |
|---|---|---|---|
| 13-Jan | 9-9:30 AM | Jordan Seto | Pseudonatural Products for Chemical Biology and Drug Discovery |
| 13-Jan | 9:30-10 AM | Zhaoyuan Sun | Transport mechanism and drug discovery of human monocarboxylate transporter 1 |
| 20-Jan | 9-9:30 AM | Vincent White | De novo discovery of a molecular glue–like macrocyclic peptide that induces MCL1 homodimerization |
| 20-Jan | 9:30-10 AM | Caroline Jacky | Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy |
| 27-Jan | 9-9:30 AM | Benjamin Baldwin | Triazenolysis of alkenes as an aza version of ozonolysis |
| 27-Jan | 9:30-10 AM | LinJun Su | Deep learning–guided design of dynamic proteins |
| 3-Feb | 9-9:30 AM | Joshua Davis | In-Cell Approach to Evaluate E3 Ligases for Use in Targeted Protein Degradation |
| 10-Feb | 9-10 AM | Yuzhao Zhang | Discovery of heparanase small-molecule binders using combined in silico and in vitro methods |
| 17-Feb | 9-10 AM | Allison C Lynch | Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers |
| 24-Feb | 9-10 AM | Yunlu Liu | Structure-based drug design with equivariant diffusion models |
| 3-Mar | 9-10 AM | Kuntala Dey | Identification of Actionable Targeted Protein Degradation Effector Sites through Site-Specific Ligand Incorporation-Induced Proximity (SLIP) |
| 10-Mar | 9-10 AM | Emma K Ellis | Activity of GPCR-targeted drugs influenced by human gut microbiota metabolism |
| 24-Mar | 9-10 AM | Annan Sun | Covalent Recruitment of NEDD4 for Targeted Protein Degradation: Rational Design of Small Molecular Degraders |
| 31-Mar | 9-10 AM | Meng-Lun Hsieh | A broad-spectrum lasso peptide antibiotic targeting the bacterial ribosome |
| 7-Apr | 9-10 AM | Vanisa Petriti | |
| 14-Apr | 9-10 AM | Yujia Jiang | –– |
| 21-Apr | 9-10 AM | Johnathan D Somers |
Fall 2025 Seminar Schedule
| Date | Time | Presenter | Seminar title |
|---|---|---|---|
| 26-Aug | 9-10 AM | Anna Gioseffi | Lab safety education |
| 2-Sep | 9-9:30 AM, 9:30- 10 AM | Xingui Liu, Lina Cui | Course introduction, Meet the Graduate Coordinator |
| 9-Sep | 9-9:30 AM | Peter A Ramdhan | TIDGN: A Transfer Learning Framework for Predicting Interactions of Intrinsically Disordered Proteins with High Conformational Dynamics |
| 9-Sep | 9:30-10 AM | Seif A Abouheif | Neuroprotective triterpenoids from Astragalus membranaceus stems and leaves: Anti-inflammatory and anti-apoptotic mechanisms for memory improvement via in vivo and in vitro models |
| 16-Sep | 9-10 AM | Amber Moore and Laura Schaecher | Research Integrity & Transparency |
| 23-Sep | 9-9:30 AM | Hsin-Ying Tsai | Evolution-inspired engineering of nonribosomal peptide synthetases |
| 23-Sep | 9:30-10 AM | Christian Barnard | Identification and Characterization of a Blood−Brain Barrier Penetrant Inositol Hexakisphosphate Kinase (IP6K) Inhibitor |
| 30-Sep | 9-9:30 AM | Chi-Yuan Liu | Targeted protein relocalization via protein transport coupling |
| 30-Sep | 9:30-10 AM | Yifan Wang | Anomanolide C suppresses tumor progression and metastasis by ubiquitinating GPX4-driven autophagy-dependent ferroptosis in triple negative breast cancer |
| 7-Oct | 9-10 AM | Drew Kwitchoff | Orally Bioavailable Dopamine D1/D5 Receptor-Biased Agonists to Study the Role of β-Arrestin in Treatment-Related Dyskinesia in Parkinson’s Disease |
| 14-Oct | 9-10 AM | Derrik Scharland | Redirecting the pioneering function of FOXA1 with covalent small molecules |
| 21-Oct | 9-10 AM | Campbell Eckhardt | Rational multienzyme architecture design with iMARS |
| 28-Oct | 9-10 AM | Gujie Xu | Optimization of Single Relaxin B‑Chain Peptide Leads to the Identification of R2R01, a Potent, Long-Acting RXFP1 Agonist for Cardiovascular and Renal Diseases |
| 4-Nov | 9-10 AM | Mengting Li | Computational design of serine hydrolases |
| 18-Nov | 9-10 AM | Liangwen Gu | Use of a Cyclic α‑Alkylidene-β-Diketone as a Cleavable Linker Strategy for Antibody-Drug Conjugates |
| 2-Dec | 9-10 AM | Jeremiah Batucan | Medicinal Chemistry Progression of Sapanisertib, the Anticancer and Dual Plasmodium Phosphatidylinositol 4-Kinase Beta and cGMP-Dependent Protein Kinase Inhibitor, for Malaria |